Mifepristone Access and Outcomes
Summary
Summary
This project explores the impact of Canada’s unique regulatory approach to mifepristone, which is used for medication abortion. In Canada, there is potential for increased uptake of mifepristone due to regulations which allow non-physician providers to prescribe it, pharmacists to dispense it, and patients to ingest it without direct supervision. Our research is being conducted at ICES. We are using administrative health date to:
- examine the impact of mifepristone medical abortion on abortion service access in Ontario,
- identify abortion related adverse event rates before and after introduction of mifepristone medical abortion in Ontario, and
- compare abortion service health system costs before and after introduction of mifepristone medical abortion in Ontario.
Project Status:
In progress
Publications
1. Schummers L, McGrail K, Darling EK, Dunn S, Gayowsky A, Kaczorowski J, Norman W. A more accurate approach to define abortion cohorts using linked administrative data: an application to Ontario, Canada. International Journal of Population Data Science. 2022; https://doi.org/10.23889/ijpds.v7i1.1700
2. Schummers L, Darling EK, Dunn S, McGrail K, Gaywosky A, Law MR, Laba T-L, Norman WV. Abortion utilization and safety with normally prescribed mifepristone in Canada. NEJM 2022; 386:57-67. DOI: 10.1056/NEJMsa2109779
2. Schummers L, Darling EK, Dunn S, McGrail K, Gaywosky A, Law MR, Laba T-L, Norman WV. Abortion utilization and safety with normally prescribed mifepristone in Canada. NEJM 2022; 386:57-67. DOI: 10.1056/NEJMsa2109779
